In Vivo TLR9 Inhibition Attenuates CpG-Induced Myocardial Dysfunction
Figure 4
(a)–(f) Hemodynamic parameters, (a) left ventricular systolic pressure (LVSP), (b) stroke volume (SV), (c) end-diastolic volume (EDV), (d) cardiac output (CO), (e) velocity of pressure increase (), and (f) velocity of pressure decrease () monitored with a pressure-volume catheter 6 h after stimulation with the TLR9 agonist 1668-thioate. Bars of TLR9-D are striated (mean ± SEM; /group, *; *also indicates the significant group).
